Salute e Benessere

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar…

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD)Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025)— Alvotech...
Nasdaq GlobeNewswire
21/08/2025

ESC Congress 2025: OMRON Healthcare to Spotlight Risks of Undiagnosed Heart…

Logo: https://kyodonewsprwire.jp/img/202508143587-O1-OOpNextt Logo:https://kyodonewsprwire.jp/img/202508143587-O1-OOpNextt Image:https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202508143587/_prw_PI2fl_hc510BeN.png The annual ESC Congress is one of the most important gatherings for the global cardiology community, bringing together medical professionals, healthtech providers, and other allied professions to discuss the latest research and advances in the field. The 2025...
PR Newswire
21/08/2025

Invitation to presentation of BioArctic's second quarter report for April - June…

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions.Webcast: https://bioarctic.events.inderes.com/q2-report-2025/register If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://bioarctic.events.inderes.com/q2-report-2025/register If you wish to participate via teleconference, please register on the link below. After registration...
PR Newswire
21/08/2025

Three French healthcare providers digitize pathology with Sectra to enhance…

By replacing microscopes with a digital workflow, the pathologists get instant, and when needed, remote access to digital images of tissue samples. Sectra's solution combines worklists, reporting, and image review in a single application optimized for primary diagnostics. It also enables the healthcare providers to utilize AI to further improve pathology workflows and cancer care. By replacing microscopes with a digital workflow, the pathologists get instant, and when needed, remote access to...
PR Newswire
21/08/2025

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to…

This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond theSellersvillesite. Piramal's Ahmedabad PPDS,Indiasite...
PR Newswire
21/08/2025

Novonesis delivered 9% organic sales growth in H1 and full-year outlook range…

COPENHAGEN, Denmark – August 21, 2025.Novonesis delivered 9% organic sales growth in H1 and full-year outlook range narrowed to 6-8%.Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a strong foundation...
Nasdaq GlobeNewswire
21/08/2025

Interim report H1 2025

9% organic sales growth in H1 and FY outlook range narrowed to 6-8% Ester Baiget, President & CEO: “I’m very pleased with 9% organic sales growth in the first half of the year. Demand for our biosolutions is strong, and consequently, we are lifting the lower end of our full-year guidance to 6-8% organic sales growth. Our profitability also remains solid, despite strong headwinds from currencies. With a robust foundation in place, we are well positioned to accelerate into our next...
Nasdaq GlobeNewswire
21/08/2025

Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in…

Press ReleaseNicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepointsNCX 470 0.1% was safe and...
Nasdaq GlobeNewswire
21/08/2025

Interim Report Q2 2025: Commercial and operational agility drove market share…

HighlightsThe Hearing division delivered 8% organic revenue growth driven by broad-based market share gains of ReSound Vivia across global markets growing below structural trends. The strong growth led to 12% growth in divisional profit, equaling a divisional profit margin of 36% driven by operating leverageThe Enterprise division was – as expected – challenged by market uncertainty due to the global trade environment. The organic revenue growth was -7% due to the market uncertainty and...
Nasdaq GlobeNewswire
21/08/2025

Global Minimal Residual Disease Testing Market Gearing Up for Outstanding…

Key Takeaways from the Minimal Residual Disease Testing Market Report Key Takeaways from the Minimal Residual Disease Testing Market Report To read more about the latest highlights related to the minimal residual disease testing market, get a snapshot of the key highlights entailed in theGlobal Minimal Residual Disease Testing Market Report Minimal Residual Disease Testing Overview Minimal residual disease testing refers to the detection of small numbers of cancer cells that...
PR Newswire
20/08/2025

HDAC Inhibitors Market Sees Upward Trajectory Across the 7MM During the Forecast…

Key Takeaways from the HDAC Inhibitors Market Report Key Takeaways from the HDAC Inhibitors Market Report Discover which indication is expected to grab the major HDAC inhibitors market share @HDAC Inhibitors Market Report HDAC Inhibitors Overview Histone deacetylases (HDACs) remove acetyl groups from both histone and non-histone proteins. Because acetylation of histones is linked to an open chromatin structure and active gene transcription, HDAC activity leads to histone...
PR Newswire
20/08/2025

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August…

Audio webcast/conference call: Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. Audio webcast/conference call: Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at ...
PR Newswire
20/08/2025

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.Copenhagen, Denmark, August 20, 2025 –Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:As of 19 August...
Nasdaq GlobeNewswire
20/08/2025

APIX Biosciences NV announces new advances in Honeybee Nutrition

announces the publication in Nature, by APIX Biosciences’ Scientific Founder Prof. Geraldine Wright and her team, on the production of plant-sterols in a yeast synthetic biology platform and the role of these phytosterols in honeybee nutrition ( https://doi.org/10.1038/s41586-025-09431-y ). APIX is pleased to have acquired and integrated this technology in its portfolio of technologies.“Sterols are one of many nutrient classes honeybees require in their diet. This publication describes how...
Nasdaq GlobeNewswire
20/08/2025

2030 financial targets announced: Organic sales growth acceleration, margin…

COPENHAGEN, Denmark - August 20, 2025.Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%.Novonesis is well positioned to continue to drive strong performance in biosolutions. The...
Nasdaq GlobeNewswire
20/08/2025

King Faisal Specialist Hospital Provides Nearly 300,000 Virtual Consultations in…

Launched in 2021, the virtual consultation service was introduced to reduce travel burdens for patients in remote areas. For many, particularly the elderly and those living with chronic conditions, it has eliminated the need for repeated hospital visits, improved quality of life, and removed financial and logistical barriers by connecting them directly with specialists from home.With an average of more than 800 virtual visits each day, the service has eased pressure on outpatient...
Nasdaq GlobeNewswire
20/08/2025

OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer

NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep international expertise in capital markets, financial strategy, and governance to the company.Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic financial leadership, both in private and...
Nasdaq GlobeNewswire
20/08/2025

2030 financial targets announced: Organic sales growth acceleration, margin…

Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple...
Nasdaq GlobeNewswire
20/08/2025

Global Healthcare Gets a 6G Boost: Market to Grow at 77.9% CAGR Through 2040 |…

The report analyzes the global 6G market in healthcare, exploring trends, challenges, and growth drivers. It segments the market by component, application, connectivity, end user, and region, covering the major areas of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Additionally, it evaluates the competitive landscape by ranking leading companies and profiling major players. The report analyzes the global 6G market in healthcare, exploring trends,...
PR Newswire
20/08/2025

Neonatal Care Equipment Market worth $2.84 billion by 2030 with 5.6% CAGR |…

Browse in-depth TOC on "Neonatal Care Equipment Market" Browse in-depth TOC on "Neonatal Care Equipment Market" 329 - Tables 65 - Figures 326 - Pages By product,the neonatal care equipment market is divided into neonatal incubators, neonatal respiratory care devices, convertible warmers & incubators, neonatal phototherapy equipment, neonatal monitoring devices, neonatal diagnostic imaging components, infant warmers, and other neonatal care equipment. Technological...
PR Newswire
20/08/2025

In-Vitro Diagnostics Market is Poised to Reach USD 153.3 Billion by 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/in-vitro-diagnostics-market Get a Free Sample Report-https://www.skyquestt.com/sample-request/in-vitro-diagnostics-market Key U.S. IVD Market Drivers In-Vitro Diagnostics Market Dynamics The increase in the prevalence of chronic and infectious diseases, and genetic disorders like Turner syndrome, Alzheimer's disease, and Parkinson's disease, is expected to drive up demand for in-vitro diagnostics over the...
PR Newswire
20/08/2025

Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR |…

Browse in-depth TOC on "Human Microbiome Market" Browse in-depth TOC on "Human Microbiome Market" 416 - Tables 64 - Figures 371 - Pages By type,bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live bacteria products, and others segment the human microbiome market. Live bacteria products accounted for the largest share of the human microbiome market in 2024. This category includes probiotics and synbiotics, which are widely used in consumer...
PR Newswire
20/08/2025

Crisis Prevention Institute® (CPI) Appoints Andee Harris as New Chief Executive…

Harris is a seasoned executive with extensive leadership experience accelerating the growth of mission-driven organizations at the intersection of education, behavioral health, and workplace development. Most recently, she served as the CEO of Challenger, a pioneer in salesforce training, technology and consulting where she led the company through a period of accelerated innovation, digital modernization and strategic growth. She previously held executive roles at Sparrow, a provider of…
PR Newswire
20/08/2025

Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net…

The Company's international business sustained strong growth in the first half of 2025, with revenue reaching RMB 15.72 million. By June 30, the Company had commercialized 22 products in 27 countries and regions, with over 31 products under registration in 23 markets. Its global network covers 52 countries and regions through partnerships with over 60 local distributors. With overseas commercialization accelerating and revenue contribution rising, the international business is becoming a new…
PR Newswire
20/08/2025
Altri  Comunicati